Results of TroVax® in Advanced Colorectal Cancer

RNS Number : 7343X

Oxford Biomedica PLC

24 February 2017

 

Oxford BioMedica Notes Encouraging Results of the Investigator Led Phase I/II clinical trial of MVA-5T4 Immunotherapy (TroVax^®) and Low Dose Cyclophosphamide in Patients with Advanced Colorectal Cancer

~ Both Cyclophosphamide and TroVax^® independently shown to induce highly beneficial anti-tumour immune responses, resulting in significantly prolonged survival of advanced colorectal cancer patients

Oxford, UK - 24 February 2017: Oxford BioMedica plc (LSE:OXB) ("Oxford BioMedica" or "the Group"), a leading gene and cell therapy group, today notes the results from a Phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax^®) and low dose cyclophosphamide (CPM) in patients with advanced colorectal cancer (TaCTiCC). A poster was presented by the clinical investigators in a poster session at the American Society of Clinical Oncology and Society for Imumunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium on 23 February 2017 in Orlando, USA.

The poster described the open-label Phase I/II clinical trial involving 53 patients with inoperable, metastatic colorectal cancer who were randomised to receive either no treatment, low dose CPM, TroVax^® only or low dose CPM followed by TroVax^®. The primary study endpoint was to assess increased anti-5T4 responses after treatment on day 43 and the secondary endpoints were progression free /overall survival and anti-5T4 responses over the trial period.

The study findings demonstrated that significant anti-5T4 immune responses were generated at treatment day 43. Secondary analysis revealed that both CPM and TroVax^® independently induced highly beneficial anti-tumour immune responses, resulting in significant survival of end stage colorectal cancer patients, without any major toxicity. This was the first randomised study to show a benefit of immunotherapy in advanced colorectal cancer patients.

Commenting on the results, John Dawson, Chief Executive Officer of Oxford BioMedica, said: "The presentation by the Clinical Investigators of the Phase I/II TaCTiCC study at the ASCO-SITC Clinical Immuno-Oncology symposium showed the potential benefit that Oxford BioMedica's immunotherapy (TroVax^®) treatment could give to patients with advanced colorectal cancer."

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: [phone]

Jefferies (Corporate Broker):                                                  Tel: [phone]

Gil Bar-Nahum

Simon Hardy

Lee Morton

Max Jones

Nicholas Moore

Notes to editors

About Oxford BioMedica^®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

NRAPGUPAPUPMGMW